Trial record 2 of 29 for:    saracatinib

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by Baylor College of Medicine
University of Texas
University of Cincinnati
Information provided by (Responsible Party):
Tony Eissa, Baylor College of Medicine Identifier:
First received: April 15, 2014
Last updated: April 17, 2014
Last verified: April 2014

Lymphangioleiomyomatosis (LAM) is a rare lung disease that mostly affects women of childbearing age. In LAM, abnormal, muscle-like cells begin to grow out of control in the lungs. As a result, air can't move freely in and out of the lungs. In some cases, this means the lungs can't supply the body's other organs with enough oxygen.

This study is being conducted to find out what dose of a drug called saracatinib is best tolerated by people with LAM. This drug has been tested in patients with certain types of cancer but is not currently approved by the United States Food and Drug Administration (FDA). Saracatinib may work in cancer by preventing the growth, movement and invasiveness of cancer cells. The use of saracatinib to treat LAM is considered experimental. Preliminary testing already completed suggests that the study drug, saracatinib, may suppress certain substances in the lungs of patients with LAM thus may be effective in slowing down the disease process

Condition Intervention Phase
Pulmonary Lymphangioleiomyomatosis
Drug: Saracatinib
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Resource links provided by NLM:

Further study details as provided by Baylor College of Medicine:

Primary Outcome Measures:
  • Dose Determination [ Time Frame: Saracatinib will be given for 4 weeks, the subject will be followed for a total of 8 weeks. ] [ Designated as safety issue: Yes ]
    One of three escalating daily oral doses of saracatinib; 50, 125 and 175 mg. Saracatinib will be given orally once a day for four weeks. Adverse events will be monitored. The subject will receive only one of the doses as determined by the escalation of the study.

Secondary Outcome Measures:
  • Safety Profile [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]
    This objective is to generate a safety profile utilizing the data collected along with the adverse events. Subjects will be followed closely during the 4 weeks while taking drug and again for four weeks after stopping the study drug.

Other Outcome Measures:
  • Efficacy exploration [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    explore the efficacy measurements (e.g., pulmonary function test, six minute walk test, and VEGF-D)

Estimated Enrollment: 12
Study Start Date: March 2014
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Saracatinib

Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.

More regarding dose escalation is included in intervention below.

Drug: Saracatinib
Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
Other Name: AZD0530

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients. It should be noted, however, that LAM occurs predominantly in women.
  • 18 to 65 years of age.
  • All patients must have a diagnosis of LAM as defined by one of the following:

Open lung, transbronchial or thoracic needle biopsy consistent with LAM Open or needle abdominal biopsy findings consistent with LAM Computed tomography (CT) of chest or abdomen consistent with LAM in the setting of TSC, renal AML, cystic abdominal lymphangiomas, or history of chylous effusion in the chest or abdomen CT of chest consistent with LAM plus serum VEGF-D > 800 pg/ml In cases where the diagnosis of LAM is based on biopsy, review of the pathology specimens by pathologists who are experienced with LAM, such as those at the NIH or the Mayo Clinic, will be obtained (if not done so previously).

Exclusion Criteria:

  • Current infection.
  • Major surgery within the past 2 months
  • Advanced hematologic, renal, hepatic, or metabolic diseases
  • The use of another investigational drug within 30 days
  • The use of mTOR inhibitors within 30 days
  • Previous lung transplantation or active on transplant list.
  • Inability to attend scheduled clinic visits
  • Inability to give informed consent
  • Inability to perform pulmonary function testing
  • History of malignancy in the past two years, other than squamous or basal cell skin cancer or mild cervical cancer.
  • Nursing mothers
  • Current or planned pregnancy.
  • Not using adequate contraception (in woman of childbearing potential).
  • Significant clinical change in health in the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02116712

Contact: Caryn O Pope, RRT 713-873-2471
Contact: Tony Eissa, MD 713-873-8959

United States, Ohio
University of Cincinnati Not yet recruiting
Cincinnati, Ohio, United States, 45267
Contact: Tammy Roads    513-558-2148   
Principal Investigator: Frank X McCormack, MD         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Caryn O Pope, RRT    713-873-2471   
Contact: Nicola A Hanania, MD    713-873-2468   
Principal Investigator: Nicola A Hanania, MD         
University of Texas Health Science Center-Houston Recruiting
Houston, Texas, United States, 77030
Contact: Stacy Burk, LVN    713-500-6851   
Contact: , MD         
Principal Investigator: Khalid F Almoosa, MD         
Sponsors and Collaborators
Tony Eissa
University of Texas
University of Cincinnati
Study Chair: Tony Eissa, MD Baylor College of Medicine
Principal Investigator: Nicola A Hanania, MD Baylor College of Medicine - Ben Taub Hospital
Principal Investigator: Khalid Almoosa, MD The University of Texas Health Science Center, Houston
Principal Investigator: Frank McCormack, MD University of Cincinnati
  More Information

No publications provided

Responsible Party: Tony Eissa, Professor of Medicine - Pulmonary, Baylor College of Medicine Identifier: NCT02116712     History of Changes
Other Study ID Numbers: SLAM 7601
Study First Received: April 15, 2014
Last Updated: April 17, 2014
Health Authority: United States: Food and Drug Administration
United States: Data and Safety Monitoring Board

Keywords provided by Baylor College of Medicine:

Additional relevant MeSH terms:
Lymphatic Vessel Tumors
Neoplasms by Histologic Type
Perivascular Epithelioid Cell Neoplasms
Neoplasms, Connective and Soft Tissue
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 22, 2014